Discover
mirikizumab (LY3074828) / Eli LillyMirikizumab: Top-line data from P3 trials OASIS-1 (NCT03482011) and OASIS-2 (NCT03535194) for psoriasis in 2020 (Eli Lilly) - Dec 18, 2019 - 2020 Financial Guidance Call [Screenshot]Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallIlumya regulatory estimate: Approval by 2023 in China for psoriasis - Dec 19, 2019 - A subscription to Thomson ONE is required to gain full access to report 68380316; Page no: 7; REPORT TITLE: "China medical system: Time to price in some pipeline value; Raise PT "; AUTHOR: Hu, Yolanda, et al; DATE: 11/21/2019Stelara (ustekinumab) / J&JStelara: “The Committee discussed the issues identified in this application relating to some quality and clinical aspects as well as the RMP [extension of indication to include a new population for Stelara solution for injection in children aged 6 to 12 years with moderate to severe psoriasis based on the results of study CNTO1275PSO3013].” (EMEA) - Dec 20, 2019 - CHMP Final Minutes for the meeting on 14-17 October 2019: “The Committee adopted a request for supplementary information with a specific timetable.”Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallSAIL: Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (clinicaltrials.gov) - Dec 18, 2019 - P; N=430; Recruiting; Sponsor: Almirall, S.A.Olumiant (baricitinib) / Incyte, Eli Lilly; Taltz (ixekizumab) / Eli LillyLilly announces 2020 financial guidance, updates 2019 guidance (Eli Lilly Press Release) - Dec 17, 2019 - "The company anticipates 2020 revenue between $23.6 billion and $24.1 billion. Meeting its 2020 revenue forecast would allow the company to achieve or exceed the 7 percent revenue CAGR target it previously communicated for the time period 2015 – 2020. Revenue growth is expected to be driven by volume from key growth products including...Taltz®...Olumiant®, Emgality...Reyvow."Taltz (ixekizumab) / Eli Lilly; Cosentyx (secukinumab) / Novartis; Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab (clinicaltrials.gov) - Dec 16, 2019 - P3b; N=250; Recruiting; Sponsor: AbbVie; N=365 --> 250Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallIlumya sales projection: $175M by FY2022 (Nomura) - Dec 16, 2019 - A subscription to Thomson ONE is required to gain full access to report 68399991; Page no: 1; REPORT TITLE: "Sun Pharmaceutical Industries (SUNP IN, Buy) - Retain buy with reduced TP of INR 525"; AUTHOR: Mukherjee, Saion, et al; DATE: 11/25/2019
